We describe four patients who developed symptomatic hypoglycaemia following treatment of hyperkalaemia with insulin and dextrose. Two patients had a delayed onset of hypoglycaemia, between 5 and 6 hours after treatment despite use of a 'soluble' type of insulin. A review of the literature revealed a variety of insulin and dextrose regimes but no research to assess the metabolic effects of such therapy in patients with renal failure. The possibility of significant hypoglycaemia following -use of insulin and dextrose in the recommended dosages is rarely mentioned.
Introduction
The use of intravenous insulin and dextrose in the treatment of hyperkalaemia is well established. However, the optimum dose of insulin per gram dextrose administered is not generally agreed. It has been suggested that intravenous hypertonic dextrose alone may be all that is required unless the patient is diabetic1 but dosages of 0.2 IU insulin/gram dextrose,2'3 0.2-0.4 IU/g,4'5 0.5 IU/g,6 0.6 IU/g,7 and up to 1.0 IU/g, e.g. 50 units soluble insulin with 100ml 50% dextrose8'9 have been advised.
Recently we have seen four patients who developed symptomatic hypoglycaemia following treatment of hyperkalaemia with insulin and dextrose. None had received any other hypoglycaemic agent, they were not diabetic and there was no evidence of hepatic failure. One hundred ml 50% dextrose were given intravenously with prompt resolution of his symptoms. A 32 year old man who had been on haemodialysis for 12 years was admitted with a thrombosed arterio-venous (AV) fistula. Thrombectomy was performed under local anaesthetic on the day of admission. A subclavian dialysis cannula was inserted via which haemodialysis was performed the following day. Two days later a further exploration of the AV fistula was carried out. However, prior to surgery the plasma potassium was 7.3 mmol/l. Fifty ml 50% dextrose and 10U actrapid insulin (0.4 IU/g) were therefore administered intravenously. Post-operatively, and some 6 hours after receiving insulin and dextrose the patient was commenced on haemodialysis. After 30 minutes dialysis he suffered a cardiac arrest at which time blood glucose was found to be 1.1 mmol/l and potassium 4.5 mmol/l. The cardiac arrest was considered to be multifactorial in origin with metabolic abnormalities, including hypoglycaemia, playing a prominent role. The patient was resuscitated and given one hundred ml 50% dextrose which corrected the hypoglycaemia. However, he remained unconscious and required ventilation for 72 hours before eventually making a full recovery.
Discussion
It has been known for many years that insulin causes a shift of potassium from extracellular to intracellular fluids thereby reducing the concentration in plasma. Hypertonic glucose alone given intravenously can produce a fall in plasma potassium in normal subjects due to the action of endogenous insulin.10 However, most clinicians add small doses of insulin to the intravenous glucose infusion in order to accelerate and accentuate the potassium lowering effect. We are not aware of any research in humans which has compared varying dosages of insulin and dextrose in the treatment of hyperkalaemia.
The cases we describe demonstrate that there is no 'correct' dose of insulin per gram dextrose to suit every circumstance. Our third patient received an inappropriately high dose of insulin per gram dextrose but the three others developed hypoglycaemia when dosages within the advised range were given (0.56, 0.4 and 0.4 IU insulin/g dextrose respectively). The response to insulin will depend upon many factors including the patient's age, general level of nutrition, any period of starvation, e.g. prior to surgery, and concurrent use of non-selective beta blockers which may slow recovery from hypoglycaemia through inhibition of the glycogenolytic and lipolytic action of endogenous catecholamines. Moreover, in patients with renal failure the metabolism of insulin is impaired and the onset of hypoglycaemia may be delayed;1" note that in cases 3 and 4 symptomatic hypoglycaemia did not occur until five and six hours after receiving insulin and dextrose. Uraemic factors, too, may retard the recovery of blood glucose concentration after an episode of insulin induced hypoglycaemia, possibly through decreased availability of hepatic glycogen. '2 If insulin is used with hypertonic glucose to treat hyperkalaemia then its dosage (IU/g) must be adjusted to take account of these factors. A fixed dose of insulin per gram dextrose is not suitable for all circumstances. Also, more importantly, blood glucose concentrations should be monitored regularly for several hours after the administration of insulin. This simple advice is not usually found in most popular textbooks and the possibility of hypoglycaemia occurring following use of insulin and dextrose in the dosages they recommend is rarely mentioned. 
